Despite the impact of proteasome inhibitors and immunomodulatory agents, infusional chemotherapy regimens continue to be used for patients with multiple myeloma.
READ FULL ARTICLE
From Wiley Online Library
Three salvage infusional chemotherapy regimens produced similar responses, survival, and adverse events in patients with multiple myeloma, according to an article published online in the journal Cancer.
In a single-institution study, three salvage chemotherapy regimens were compared among 107 patients with recurrent multiple myeloma who were treated using one of three salvage chemotherapy regimens.
Fifty-two patients received dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP) cohort; 22 received bortezomib, thalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide (VTD-PACE) treatment group; and 33 patients received cyclophosphamide, vincristine, doxorubicin, and dexamethasone (CVAD).
There were some differences between groups. For example, patients treated with CVAD had a higher baseline creatinine (P<0.001) and those treated with VTD-PACE had greater prior use of infusional chemotherapy (P<0.001).
Regarding patient response, no significant differences were reported among the three groups (55% overall; P=0.18).
Similarly, no significantly different outcomes were reported for survival among the three groups: overall median progression-free survival of 4.5 months (95% CI: 3.6, 5.5 months; P=0.8) and a median overall survival of 8.5 months (95% CI: 6.1, 11 months; P=0.8). DCEP, VTD-PACE, and CVAD demonstrated similar clinical adverse events; however, it was noted that DCEP was suggested as having fewer events.
Sixty-two percent of patients with the intent to transplant were successfully bridged to transplant without further therapy (P=0.9).
Furthermore, the intent-to-transplant population had greater response outcomes (OR, 3.40; P=0.01), superior progression-free survival (HR, 0.28; P<0.001), and increased overall survival (HR, 0.19; P<0.001).
Despite the impact of proteasome inhibitors and immunomodulatory agents, infusional chemotherapy regimens continue to be used for patients with multiple myeloma.
READ FULL ARTICLE
From Wiley Online Library
You’ve read {{metering-count}} of {{metering-total}} articles this month.
We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.
{{login-button}} {{register-button}}
Want to view more content from Cancer Therapy Advisor?
Register now at no charge to access unlimited clinical news, full-length features, case studies, conference coverage, and more.
{{login-button}} {{register-button}}
Please login or register first to view this content.